Skip to content

Study · In vitro (cells) · 2022

5 results

[Gly14]-Humanin inhibits an angiotensin II-induced vascular smooth muscle cell phenotypic switch via ameliorating intracellular oxidative stress.

Xie Y, Zhang J, Zhang M, Jiang L

Human & experimental toxicology1 Jan 2022Cited by 5 (Europe PMC)

PMID36289015 (opens in a new tab)DOI10.1177/09603271221136208 (opens in a new tab)PepBankPUB-36289015
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In angiotensin II-stimulated vascular smooth muscle cells, [Gly14]-Humanin inhibited cell proliferation.

    In plain wordsIn cells, a humanin analogue reduced the growth of blood vessel muscle cells stimulated by angiotensin II.

    Peptide
    Humanin
    Outcome
    DecreaseVSMC proliferation after AngII
    Study

    n: not reported in source

    Angiotensin II-stimulated vascular smooth muscle cells (VSMCs)
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results showed that HNG inhibited AngII-induced VSMC proliferation and migration and maintained a stable VSMC contractile phenotype.
    1 context sentence
    Summary · context
    The roles of [Gly14]-Humanin in AngII-stimulated VSMCs proliferation and migration was detected by CCK-8 assay, Cell cycle analysis, wound healing assay, trsnswell assay and western blot.
  2. 02LabIn vitro (cells)Activity measurement

    In angiotensin II-stimulated vascular smooth muscle cells, [Gly14]-Humanin inhibited cell migration.

    In plain wordsIn cells, a humanin analogue reduced the movement of blood vessel muscle cells stimulated by angiotensin II.

    Peptide
    Humanin
    Outcome
    DecreaseVSMC migration after AngII
    Study

    n: not reported in source

    Angiotensin II-stimulated vascular smooth muscle cells (VSMCs)
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results showed that HNG inhibited AngII-induced VSMC proliferation and migration and maintained a stable VSMC contractile phenotype.
    1 context sentence
    Summary · context
    The roles of [Gly14]-Humanin in AngII-stimulated VSMCs proliferation and migration was detected by CCK-8 assay, Cell cycle analysis, wound healing assay, trsnswell assay and western blot.
  3. 03LabIn vitro (cells)Activity measurement

    In angiotensin II-stimulated vascular smooth muscle cells, [Gly14]-Humanin maintained a stable contractile phenotype and so suppressed the phenotypic switch.

    In plain wordsIn cells, a humanin analogue helped blood vessel muscle cells keep their normal contractile type despite angiotensin II.

    Peptide
    Humanin
    Outcome
    DecreaseVSMC phenotypic switch (contractile phenotype)
    Study

    n: not reported in source

    Angiotensin II-stimulated vascular smooth muscle cells (VSMCs)
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results showed that HNG inhibited AngII-induced VSMC proliferation and migration and maintained a stable VSMC contractile phenotype.
    2 context sentences
    Summary · context
    In conclusion, the results suggested that HNG ameliorated intracellular oxidative stress by inhibiting NAD(P)H oxidase activity, thereby suppressing the AngII-induced VSMC phenotype switch.
    Summary · context
    The roles of [Gly14]-Humanin in AngII-stimulated VSMCs proliferation and migration was detected by CCK-8 assay, Cell cycle analysis, wound healing assay, trsnswell assay and western blot.
  4. 04LabIn vitro (cells)Mechanism

    In angiotensin II-stimulated vascular smooth muscle cells, [Gly14]-Humanin reduced the level of oxidative stress.

    In plain wordsIn cells, a humanin analogue lowered the oxidative stress caused by angiotensin II in blood vessel muscle cells.

    Peptide
    Humanin
    Outcome
    DecreaseAngII-induced oxidative stress
    Study

    n: not reported in source

    Angiotensin II-stimulated vascular smooth muscle cells (VSMCs)
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, HNG reduced the level of AngII-induced oxidative stress in vascular smooth muscle cells.
    1 context sentence
    Summary · context
    The roles of [Gly14]-Humanin in AngII-stimulated VSMCs proliferation and migration was detected by CCK-8 assay, Cell cycle analysis, wound healing assay, trsnswell assay and western blot.
  5. 05LabIn vitro (cells)Mechanism

    In angiotensin II-stimulated vascular smooth muscle cells, [Gly14]-Humanin reduced oxidative stress possibly by inhibiting NAD(P)H oxidase activity.

    In plain wordsIn cells, a humanin analogue may lower oxidative stress by blocking an enzyme called NADPH oxidase.

    Peptide
    Humanin
    Outcome
    DecreaseNAD(P)H oxidase activity
    Study

    n: not reported in source

    Angiotensin II-stimulated vascular smooth muscle cells (VSMCs)
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This process could be accomplished by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity. In conclusion, the results suggested that HNG ameliorated intracellular oxidative stress by inhibiting NAD(P)H oxidase activity, thereby suppressing the AngII-induced VSMC phenotype switch.
    1 context sentence
    Summary · context
    The roles of [Gly14]-Humanin in AngII-stimulated VSMCs proliferation and migration was detected by CCK-8 assay, Cell cycle analysis, wound healing assay, trsnswell assay and western blot.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.